When given as a first-line therapy, Libtayo (cemiplimab) prolonged the survival of patients with advanced non-small cell lung cancer (NSCLC), compared with platinum-based chemotherapy, according to early data from a Phase 3 trial. In addition to improving survival, Libtayo increased the proportion of people who responded to treatment, and lowered their risk of death or disease progression, compared with chemo. These positive findings are expected to form the basis of future submissions to U.S. and…
You must be logged in to read/download the full post.
The post Libtayo First-line Treatment Prolongs Survival in Advanced NSCLC, Early Trial Data Show appeared first on BioNewsFeeds.